Mayne Pharma adds two products to its Australian portfolio
Filed with ASX · · 2 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- FDA approval and first generic launch of Acticlate tablets
- Clarification statement
- Mayne Pharma acquires rights to generic Duragesic in the US
- License and supply agreement for generic Nuvaring in the US
- 2017 Half Year Media Release
Later from Mayne Pharma
- Mayne Pharma launches clozapine tablets in the US
- 2017 CEOs Speech
- 2018 Half Year Media Release
- 2018 Half Year Investor Presentation
- First generic launch of Ritalin LA 10mg capsules in the US
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma